Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...